Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

[1]  P. Formenty,et al.  Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors — Final Report , 2017, The New England journal of medicine.

[2]  Jens H Kuhn,et al.  Molecular Evidence of Sexual Transmission of Ebola Virus. , 2015, The New England journal of medicine.

[3]  T. Fletcher,et al.  Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. , 2015, The Lancet. Infectious diseases.

[4]  Jeffrey R. Kugelman,et al.  Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. , 2015, Cell reports.

[5]  Antonio Lazcano,et al.  Structural Analysis of Monomeric RNA-Dependent Polymerases: Evolutionary and Therapeutic Implications , 2015, PloS one.

[6]  Justine R. Smith,et al.  Persistence of Ebola Virus in Ocular Fluid during Convalescence. , 2015, The New England journal of medicine.

[7]  E. Dunn,et al.  Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter , 2015, Journal of Virology.

[8]  N. Snead,et al.  Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates , 2015, Nature.

[9]  Jon Cohen,et al.  Infectious diseases. Ebola drug trials lurch ahead. , 2015, Science.

[10]  T. Bell,et al.  Characterization of clinical and immunological parameters during Ebola virus infection of rhesus macaques. , 2015, Viral immunology.

[11]  Joshua C. Johnson,et al.  Euthanasia Assessment in Ebola Virus Infected Nonhuman Primates , 2014, Viruses.

[12]  J. Strong,et al.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ , 2014, Nature.

[13]  S. Nichol,et al.  High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. , 2014, Antiviral research.

[14]  S. Günther,et al.  Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. , 2014, Antiviral research.

[15]  R. Lenk,et al.  Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. , 2014, Antiviral research.

[16]  Gianluca Pegoraro,et al.  Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 , 2014, Nature.

[17]  S. Noton,et al.  Respiratory Syncytial Virus Polymerase Can Initiate Transcription from Position 3 of the Leader Promoter , 2013, Journal of Virology.

[18]  Jens H. Kuhn,et al.  Ebola Virus Genome Plasticity as a Marker of Its Passaging History: A Comparison of In Vitro Passaging to Non-Human Primate Infection , 2012, PloS one.

[19]  Lisa Hensley,et al.  Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques , 2012, Proceedings of the National Academy of Sciences.

[20]  Kayoko Ohura,et al.  Species difference of esterase expression and hydrolase activity in plasma. , 2012, Journal of pharmaceutical sciences.

[21]  S. Noton,et al.  The Respiratory Syncytial Virus Polymerase Has Multiple RNA Synthesis Activities at the Promoter , 2012, PLoS pathogens.

[22]  A. Ray,et al.  Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides , 2012, Bioorganic & Medicinal Chemistry Letters.

[23]  J. Arnold,et al.  Identification of Multiple Rate-limiting Steps during the Human Mitochondrial Transcription Cycle in Vitro* , 2010, The Journal of Biological Chemistry.

[24]  William A. Lee,et al.  Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. , 2009, Molecular pharmaceutics.

[25]  M. Otto,et al.  The Mechanism of Action of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methylcytidine Involves a Second Metabolic Pathway Leading to β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine 5′-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase , 2007, Antimicrobial Agents and Chemotherapy.

[26]  C. Goldsmith,et al.  Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. , 2005, Virology.

[27]  R. Shao,et al.  Human microvascular endothelial cells immortalized with human telomerase catalytic protein: a model for the study of in vitro angiogenesis. , 2004, Biochemical and biophysical research communications.

[28]  M. Lado,et al.  Sequelae of Ebola Virus Disease , 2018 .

[29]  G. Olinger,et al.  The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. , 2016, Antiviral research.

[30]  D. Bausch,et al.  Sequelae of Ebola Virus Disease, Kenema District, Sierra Leone. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  J. Kuhn.  Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. , 2008, Archives of virology. Supplementum.

[32]  B. Simoneau,et al.  Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. , 2004, Nucleic acids research.